CHLA Clinical Research Studies

Having volunteers participate in research studies and clinical trials is critical to our research efforts. Thousands of children and families are involved in our patient-centered studies every year. Many of the treatments used today are based on the results of past research studies and clinical trials conducted with our patients. Our scientific and clinical experts take the best ideas from the laboratory -- to the patient -- in the form of promising new treatments.

By searching our study directory, you may identify research that could impact the life of your child or of another child you know. Because the number of available research studies and clinical trials for children nationwide is small, every participant makes a significant contribution.

In addition to enrolling children with certain diseases in order to study treatments and prevention of those diseases, we also need to study healthy children. Ask your child’s doctor about volunteer study options that may be suitable for your child.

Please contact the study staff listed in your search results for more information.

Search by Keyword:    

Back to the full listing

Study Details - ID: CHLA-18-00070
Health/Science/Disease Category:
Hepatatis B
Short Name:
GS-US-320-1092
Full Title of Study:
A Randomized, Double-Blind Evaluation of the Pharmacokinetics, Safety, and Antiviral Efficacy of Tenofovir Alafenamide (TAF) in Adolescents with Chronic Hepatitis B Virus Infection (GS-US-320-1092)
Phase/Type of Study:
Phase 3
Purpose of Research:
To find out the effects of tenofovir alafenamide (TAF) on children and adolescents with chronic hepatitus B
Eligibility:
Children age 2 to < 18 years old with documented evidence of Chronic Hepatitis B (e.g. HBsAg-positive for ≥ 6 months)
Time Commitment/Requirements:
240 weeks with 15 visits. Stipend and travel reimbursment provided.
Primary Investigator:
Chuan-Hao Lin, MD
Coordinator Contact Name:
Sarah Koch
Phone Number:
(323) 361-7877
Email:
skoch@chla.usc.edu
Clinical Trials .Gov Identifier:
NCT02932150